CombiGene receives €3.3m from Horizon 2020

Published: 23-May-2018

Horizon 2020, the EU framework programme for research and development, will invest in CombiGene’s ongoing development and commercialisation of its gene therapy project focussing on difficult-to-treat epilepsy

CombiGene has been granted €3.3 million in the latest Phase II round in the Horizon 2020 SME Instrument programme. The aim of the project is development and commercialisation of the company’s gene therapy project focusing on difficult-to-treat epilepsy.

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies.

Jan Nilsson, CEO, CombiGene, said: “GAEU has in a significant way contributed to the successful outcome of our Horizon 2020 application. Both their experience of the complex application procedure and the professional hands-on support that we got throughout the entire process were very valuable. I look forward to a continued cooperation with them in the future.”

GAEU Consulting wrote the EU application and guided the research company through the application procedure.

Tomasz Wasik, Head of GAEU Horizon 2020 Centre of Excellence, said: “Our formula is to put together a tailor-made team of experts with high commercial and academic acumen.”

GAEU Consulting is a EU grant consultancy. GAEU Horizon 2020 Centre of Excellence in Kraków, Poland is one of Europe´s largest privately owned knowledge hubs for Horizon 2020 projects.

You may also like